Understanding the barriers and improving care in type 2 diabetes: Brazilian perspective in time to do more in diabetes by Vencio, S et al.
Vencio et al. Diabetol Metab Syndr  (2017) 9:46 
DOI 10.1186/s13098-017-0244-y
RESEARCH
Understanding the barriers 
and improving care in type 2 diabetes: Brazilian 
perspective in time to do more in diabetes
Sérgio Vencio1,7*, Päivi M. Paldánius2, Matthias Blüher3, Daniel Giannella‑Neto4^, Rafael Caiado‑Vencio5 
and W. David Strain6
Abstract 
Background: Type 2 diabetes mellitus (T2DM) is a complex disease, particularly in a continental country like Brazil. 
We attempted to understand and evaluate the perceptions and routines of Brazilians with T2DM and physicians, 
compared with other countries.
Methods: We compared the results from a 20‑min online survey in Brazil with simultaneously collated data from 
India, Japan, Spain, UK and USA.
Results: In total, 652 adults with T2DM and 337 treating physicians were enrolled, of whom 100 patients and 55 
physicians were from Brazil. The numbers of primary care physicians from the five countries were 221 versus 43 in 
Brazil, diabetes specialists were 61 versus 12. There was disconnect between the opinions of physicians and people 
with diabetes globally. Further, there were differences between clinical practices in Brazil versus the rest of the world, 
in many areas Brazilians were performing better.
Conclusions: Communication between patients and physicians should be clearer. There is an urgent need to identify 
the deficits in education, in order to address the clinical inertia within the diabetes management team. There is a 
necessity to understand the specific requirements of the Brazilian population in order to contextualise international 
guidelines and implement local changes in practice.
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Background
According to International Diabetes Federation, approxi-
mately 14.3 million people are living with diabetes in 
Brazil, and this number is expected to increase to 23.3 
million by the year 2040 [1]. Good glycaemic control 
soon after diagnosis, results in significant long-term ben-
efits, reducing the prevalence of micro and macrovascu-
lar complications. These benefits persist for many years, 
indeed the glycaemic control at diagnosis affects out-
comes many years later [2]. As diabetes progresses, the 
benefit of a good glycaemic control is attenuated and may 
even be paradoxically reversed [3].
Despite this knowledge, however, there remains a 
substantial gap between clinical aspirations and tar-
gets achieved [4]. A significant contributor to this gap 
is clinical inertia, that is, a delay in escalating therapy 
at the appropriate time. Clinical inertia has been widely 
recognised as a barrier in the management of diabetes 
for many years; however, the proportion of people with 
diabetes achieving blood pressure, lipid and glycaemic 
targets has not substantially improved [5]. Recently, the 
clinical consequences of inertia have also been associated 
with increased incidence of cardiovascular complications 
in subjects not achieving their glycaemic targets [6]. This 
is partially due to a lack of understanding of the factors 
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have explored the determinants of clinical inertia in USA, 
UK and few South-Asian countries [7–9], however, stud-
ies highlighting factors responsible for clinical inertia in 
Brazil are lacking even though the rate at which people 
being affected with diabetes is increasing alarmingly [1]. 
We conducted a survey (Time to do More) involving both 
people with diabetes and physicians across six countries 
in order to understand the potential causes of clinical 
inertia. The current subanalysis of the ‘Time to do More’ 
survey aimed to understand the perceptions and routines 
of patients with type 2 diabetes and physicians in Brazil 
in comparison to rest of the countries (USA, UK, Spain, 
India and Japan).
Methods
Details of the Time to do More survey have been pub-
lished elsewhere [10]. Briefly, individuals from the Kan-
tar Health panel of over 2500 physicians and 118,000 
patients who agreed to be contacted for research pur-
poses were randomly invited for a 20-min online survey. 
After introduction of quotas, the survey enrolled 652 
people with type 2 diabetes and 337 physicians (264 gen-
eral practitioners [GPs]; 73 specialists) treating diabetes, 
from Brazil, Japan, India, Spain, UK and USA. Fifty-five 
Brazilian physicians and 100 Brazilian people with diabe-
tes contributed to the final results (Table 1).
The survey was designed with the following objectives:
  • To identify barriers in improving the treatment of 
type 2 diabetes mellitus (T2DM) and understand the 
ways in which these can be overcome.
  • To understand clinical inertia and to what extent it 
constitutes a barrier to improving care in T2DM.
  • To explore perceptions on treating earlier and more 
aggressively.
  • To identify areas of unmet need.
Inclusion criteria are provided in Table 2.
Specific questions explored recollection from both 
physicians and people with diabetes on topics discussed 
at initial diagnosis consultation and follow-up consulta-
tions, attitudes towards complications, adequate disease 
management and perceived likelihood of achieving treat-
ment targets. Physicians were also questioned regard-
ing any modification to treatment algorithms for elderly 
patients (aged 80  years) or those with co-morbidities 
(as typified by renal impairment) compared to a typical 
50-year old individual with diabetes. Responses from 
Table 1 Demographic characteristics of the patients and physicians
BMI body mass index, PCPs primary care physicians, T2DM type 2 diabetes mellitus
USA (n = 151) UK (n = 100) Spain (n = 100) India (n = 100) Japan (n = 101) Brazil (n = 100)
Male 58% 60% 60% 62% 72% 60%
Female 42% 40% 40% 38% 28% 40%
Mean age (in years) 60.6 59.6 53.3 52.3 57.8 52.4
Mean BMI (kg/m2) 33.1 31.0 28.9 24.7 24.9 33.9
Employed full‑time 20% 26% 29% 53% 47% 48%
Employed part‑time 7% 18% 13% 13% 7% 22%
Student – – – 1% – 3%
Not working for health reasons 17% 9% 7% 4% 3% 8%
Not working for other reasons 9% 1% 27% 4% 13% 2%
Retired 47% 46% 24% 25% 31% 17%
Low income 33% 46% 85% 31% 52% 8%
Middle income 48% 28% 3% 30% 35% 23%
High income 15% 10% 4% 33% 5% 66%
Prefer not to say 4% 16% 8% 6% 8% 3%
USA (n = 75) UK (n = 50) Spain (n = 51) India (n = 50) Japan (n = 56) Brazil (n = 55)
PCPs 80% 80% 80% 80% 71% 78%
Endocrinologist/diabetologist 20% 20% 20% 20% 29% 22%
Mean time as a medical doctor 
(in years)
18 19 17 14 24 15
Average proportion of time spent 
counselling patients
97% 87% 88% 81% 92% 91%
Average number of T2DM 
patients seen in a month
170 102 125 261 209 124
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Brazil were compared against those pooled from Japan, 
India, Spain, UK and USA. Continuous data were used 
whenever possible to maximize power.
Results
Overall, 100 people with diabetes from Brazil completed 
the survey, compared to 552 from the rest of the world. 
There were 43 PCPs from Brazil, compared to 221 in the 
global pool and 12 diabetes specialists compared with 61 
from Japan, India, Spain, UK and USA.
Initial consultation visit: diagnosis
Globally, 68% of participants with diabetes received diag-
nosis from a PCP, however, in Brazil the responsibility 
was reversed, such that 53% of participants recall their 
initial diabetes counselling coming from a specialist, with 
PCPs accounting for a further 34% and other specialists, 
particularly cardiologists and nurses confirming the diag-
nosis for the rest of the participants.
This involvement with diabetes specialists at diagnosis 
translated into longer initial consultations, with a quar-
ter of Brazilians being offered  >40  min, and only 17% 
receiving  <20  min. This compares very favourably with 
figures worldwide, where 74% of initial consultations 
lasted <20 min and a further 19% of people only receiving 
between 20 and 40 min.
People with diabetes in Brazil had similar perception 
about their initial consultation, with 72% recalling longer 
than 20 min and 36% longer than 30 min. However, glob-
ally, only 61% people with diabetes recalled receiving 
consultation for at least 20 min.
Topics discussed during initial consultation
Lifestyle changes, disease and its causes and drug treat-
ment were topics discussed by almost all physicians at the 
diagnosis consultation; however, fewer patients recalled 
these topics being discussed (Fig. 1).
There were no important differences across countries in 
topics that were discussed at the diagnosis consultation 
or in the recollection of these topics. Lifestyle changes, 
such as diet and exercise, were discussed by physicians 
of all countries in nearly all cases, and the importance of 
glycaemic targets was discussed in 85% of consultations 
in Brazil and 89% globally.
A vast majority of physicians discussed the disease and 
its causes, drug treatment and risks and complications of 
T2DM, whereas about 1 in 5 patients had no recollection 
of any of these. A similar number of patients recalled dis-
cussing lifestyle changes in Brazil (13%) as in the rest of 
the world (16%). The impact of other health conditions 
on the management of diabetes was discussed only in a 
small minority of patients globally (2%); this discussion 
was twice as likely to be had in Brazil (5%). However, it 
is impossible to determine whether it was due to a higher 
prevalence of co-morbidities at diagnosis in Brazilian 
people with diabetes compared with the rest of the world. 
Fewer people from Brazil recalled the discussion about 
risks and complications of T2DM (6%) compared with 
the other countries (9%).
The longer duration of initial consultation was asso-
ciated with fewer people with diabetes having difficulty 
in understanding the topics discussed. Managing the 
disease during fasting periods was considered difficult 
to understand for 35% globally versus 20% in Brazil. 
Similarly, less than half of people with diabetes in Brazil 
struggled to understand the costs associated with treat-
ing diabetes compared with the rest of the world (10% 
vs 25% respectively), and the potential side effects of this 
Table 2 Inclusion criteria for physicians and patients
PCPs primary care physicians, T2DM type 2 diabetes mellitus
Physician screening criteria Patient screening criteria
3–35 years in practice Confirmed diagnosis of T2DM
Spend at least 70% of time in patient management
Every month see at least 50 patients with T2DM (for PCPs), 100 patients for 
specialists
Prescribes oral and/or injectableT2DM treatments
Quotas on age, gender, number of pills taken in a day, economic 
background (low, average, high income brackets)
Fig. 1 Respondents (physicians [n = 337], patients [n = 652]) recall 
of the topics discussed at the diagnosis consultation. HbA1c glyco‑
sylated haemoglobin
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treatment caused fewer concerns amongst Brazilians 
with only 12% reporting unease at treatment compared 
with 20% globally (Fig. 2).
Patients were overall satisfied with the diagnosis con-
sultation duration, and to a great extent seemed to 
understand the key topics of lifestyle changes, disease 
and its causes and drug treatment. Most of them seemed 
to accept the T2DM in a positive way.
Understanding of T2DM complications was slightly 
more limited, and there was a high level of disconnect 
between what physicians thought they had discussed and 
what patients were able to recall.
Follow‑up visits
Follow-up visits occurred fairly regularly and lasted for 
15  min on an average, with approximately 5 visits per 
year. Only a minority of people with diabetes stated they 
would like to see the physician more often. Interestingly, 
this was not associated with the actual frequency of visits. 
For example, the inter-visit length in Brazil for patients 
on diet and exercise treatment alone was approximately 
12  weeks contrasting with 17.2  weeks globally; how-
ever, 1 in 4 Brazilian patients considered visits were very 
infrequent.
Patients on oral anti-hyperglycaemic agents or insulin 
had the same average frequency of visits. The follow-up 
visits were longer in Brazil (25 min) compared with the 
rest of the world (13.4  min). As expected, most of the 
consultation was spent on taking history and diagnosis 
tests to check if the disease was under control.
Discussing complications
Majority of physicians believed they had adequately 
explained T2DM complications to their patients, includ-
ing approximately a third explaining the risk of poten-
tial early death. However, only a quarter of patients 
reported that they were worried about developing these 
complications of T2DM, while the rest were either not 
concerned or thought the risk was remote.
The complication that concerned patients the most 
was the potential of vision being affected or complica-
tions leading to blindness, with half of people reporting 
they were worried about this risk, while 21% reporting 
concern regarding cardiovascular disease. A higher pro-
portion of Brazilian physicians recalled discussing the 
importance of complications, such as circulation prob-
lems (89% vs 71%) and potential early death (44% vs 30%), 
to their patients. Paradoxically, fewer Brazilian physicians 
spent time explaining the potential impact of the disease 
on sexual health and fertility compared to the rest of the 
world (49% vs 65%).
Regarding patients’ recall memory, more international 
patients recalled the discussion about potential kidney 
problems (59% vs 39%).
The risk of developing complications had a more pro-
found effect on Brazilians; 39% were devastated to hear 
they might develop complications versus 25% in the rest 
of the world.
Only 3% of Brazilian patients were not concerned over 
the risk of developing complications compared with 
10.8% globally, which was again proportionate to the 
increased time spent at the initial consultation. This con-
cern also perpetuated into follow-up visits, where nearly 
50% more Brazilians remained concerned through fol-
low-up visits than in the rest of the world (72% vs 50% 
respectively). Despite this, apprehension over the need of 
future injectable therapy was a greater concern in Brazil 
than globally, both at diagnosis (59% vs 47%) and at fol-
low-up visits (51% vs 38%).
Fewer Brazilian physicians believed their patients did 
not understand the serious consequences of hypoglycae-
mia and the importance of reporting events (58% vs 67%). 
Concordantly, Brazilian people with diabetes were less 
likely to know very little or nothing about hypos com-
pared with the rest of the world (11% vs 21%). Further, 
Brazilians were more aware of the link between hypogly-
caemia and premature mortality compared with other 
countries (13% vs 4.4%).
Treatment algorithm
More than half of the physicians globally (53.2%) agreed 
that early treatment using combination therapy could 
help control blood sugar levels and reduce risk of compli-
cations compared with only 25% in Brazil. Consequently, 
use of combination therapy as first line was very rare, 
with most physicians reserving this powerful approach 
for second line.
Despite acknowledgement that there were important 
differences in the needs of elderly patients or those with 
co-morbidities (as represented here by people with renal 
Fig. 2 Recollection of the risks and complications discussed during 
diagnosis consultation by physicians (n = 337) and patients (n = 206)
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failure), initial treatment algorithms were remarkably 
similar, with only 7% physicians stating they would ini-
tiate combination therapy at diagnosis in patients diag-
nosed at 50  years, 9% for patients aged  >80 and 7% for 
people with renal impairment. Interestingly, in this latter 
group, Brazilian physicians were more likely to recom-
mend insulin at diagnosis compared with the rest of the 
world (34% vs 21.4%, respectively).
Approximately a quarter of people with a new diagno-
sis of diabetes did not receive drug therapy at their initial 
consultation (25% in Brazil and 23% globally); however, 
nearly half of Brazilian physicians had initiated a drug 
within a month, compared with only a third in the rest of 
the world.
When questioned about their glycosylated haemo-
globin (HbA1c), the majority of people with diabetes in 
all countries reported an HbA1c between 6.5 and 7.5%; 
however, a third of participants in Spain and Brazil did 
not know their HbA1c levels (Table 3).
When questioned about the willingness to comply with 
lifestyle advice, approximately half of patients reported 
no intention of changing their diet, and three-fifth did 
not intend to exercise more. Reasons for this willful 
non-compliance were very similar globally. Interestingly, 
proportion of those reporting financial concerns as a jus-
tification for the lack of compliance was almost identi-
cal in Brazil compared with the rest of the world (19 and 
18%).
Potential for improvement
Over half of physicians in Brazil and the rest of the world 
reported the desire for more time to discuss disease man-
agement to achieve better adherence to therapies, life-
style changes, obesity management and early screening 
(Brazil 55 and 56% globally).
Better treatment options was second on physicians’ 
wish list. This was particularly pertinent amongst Bra-
zilian physicians who desired more effective treatments, 
easier drug regimen, less frequent administration and 
medications with fewer side effects/lower risk of hypos 
(40% vs 24%). Inconsistently, Brazilian physicians were 
half as likely to request more patient education programs 
compared to international physicians (7% vs 17%).
Discussion
The Time to do More in diabetes survey demonstrated 
a clear disconnect in communication between health-
care providers and people with diabetes [10]. We have 
demonstrated that by allowing more time for patients 
in Brazil and having a greater involvement of special-
ists at an early stage, people with T2DM in Brazil have 
a good understanding of the risk of hypoglycaemia and 
increased awareness of the risks of poorly controlled dia-
betes compared with the rest of the world. Notwithstand-
ing engagement in the basic interventions such as diet 
and lifestyle remained low, albeit better in the Brazilian 
population than in the rest of the world.
In 2013, a National Health Survey in Brazil, showed 
that 6.9% of the population aged ≥18 years self-reported 
diabetes mellitus. There was a higher rate of diagno-
sis of diabetes (9.6%) among individuals with no educa-
tion or with incomplete elementary school. Rates ranged 
from 0.6% (age group 18–29 years) to 19.9% (age group 
65–74  years). There was no statistically significant dif-
ference in the diagnosis rates among whites, blacks and 
mixed race individuals [11].
At diagnosis, a quarter of consultations lasted over 
41  min, substantially more than that noted globally; 
however, this did not necessarily translate to increased 
patient satisfaction, with half of Brazilian patients believ-
ing that they did not have time to explain their fears and 
concerns. Diet and exercise were discussed at length by 
the physicians, but only two-thirds of the patients under-
stood the importance of these lifestyle interventions.
The current Brazilian guidelines, in an attempt to com-
bat clinical inertia, acknowledge that monotherapy is 
Table 3 Average blood sugar levels (HbA1c) reported by the patients during survey


















≤6.5% 28 20 14 39 18 24 5
>6.5 and ≤7.0% 21 18 31 23 12 21 25
>7.0 and ≤7.5% 16 18 25 15 17 18 23
>7.5 and ≤8.0% 5 10 9 7 10 8 6
>8.0 and ≤8.5% 3 3 – 5 2 3 4
>8.5% 1 5 2 3 6 3 4
I don’t know 26 26 19 9 35 23 33
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unlikely to achieve glycaemic control if HbA1c at diagno-
sis is >7.5% or fasting glucose is >200 mg/dL [12]. There-
fore, the guidelines recommend combination therapy 
at diagnosis in patients with high baseline HbA1c. The 
use of combination therapy at diagnosis could positively 
influence the durability of glycaemic control, changes 
in insulin sensitivity and β-cell function, time to insulin 
introduction, influences diabetic complications and the 
effects on some surrogates [13].
Three of the most important medical societies in Brazil 
(diabetes, endocrinology and cardiology) have teamed up 
to set a multidisciplinary management diabetes guideline. 
One important statement was that fighting clinical iner-
tia, defined as delay in treatment schedule at the appro-
priate time, should be effective for glycaemic targets, 
blood pressure and lipid (unpublished data). However, 
in our survey, only 25% of Brazilian physicians indicated 
they would initiate combination therapy at outset. This 
figure was similar to that reported globally, suggesting 
there is a global inertia to commencing combination 
therapy, while the physicians acknowledged the scientific 
evidence behind the introduction of early combination.
This is an interesting paradox of diabetes manage-
ment—a cardiologist would not hesitate to add multiple 
anti-platelet agents, anti-hypertensives and statin therapy 
at the diagnosis of myocardial infarction; a respiratory 
physician would routinely initiate combination of long-
acting β-2 agonist and steroid therapy if the patient was 
sufficiently compromised, yet despite established evi-
dence that a single oral agent is very unlikely to achieve 
good glycaemic control and address the key pathophysio-
logical features of diabetes, most diabetologists will nev-
ertheless implement a sub-optimal “treat-to-fail” strategy. 
Substantial training and re-education will be required in 
order to achieve adoption of current national and inter-
national guidelines to implement combination therapy at 
diagnosis.
Brazilian physicians do escalate care quickly than the 
rest of the world, with one-third more Brazilian patients 
receiving treatment shortly after diagnosis. This might 
reflect an acknowledgement of Brazilian Diabetes Soci-
ety’s guidelines, suggesting rapid escalation of treatment 
until fasting glucose  <100  mg/dL, pre-prandial glycae-
mia  <130  mg/dL, postprandial glycaemia  ≤160  mg/dL, 
and HbA1c <7% to avoid clinical inertia [12].
Importantly, there is a significant disconnect between 
what physicians say they have discussed with patients 
and what patients actually remember. Physicians wish 
to discuss issues of scientific importance; however, 
this often does not answer patients’ beliefs, fears and 
apprehensions.
Therefore, an important conclusion of this survey is 
that physicians should spend a long time determining the 
concerns, uncertainties and hesitations of people with 
diabetes before trying to impart their concern for their 
patients upon them.
The increased time spent at diagnosis consultation 
among the Brazilian patients, however resulted in a greater 
awareness of the risk of cardiovascular disease from the 
sum of multiple risk factors, and addressing these risk fac-
tors is very important for the prevention of up to two-third 
of deaths among people with diabetes [14].
At the time of the diagnosis, most of the people with 
diabetes were scared and insecure. Consequently, it is 
important to completely reassure the patients that with 
good glycaemic, lipid and blood pressure control, a nor-
mal quality of life and longevity can be achieved. Deter-
mining strategies to achieve good glycaemic control, 
including lifestyle changes, physical activity, healthy 
nutrition, self-monitoring, medical treatment compli-
ance, consultation regularity and family involvement 
should become a priority.
Another advantage of the longer time with the physi-
cian at diagnosis was a greater, albeit low understanding 
of the importance of lifestyle changes. Brazilians recall 
6% of the diagnosis consultation time spent discussing 
risks and complications of T2DM, compared with 9% 
globally.
The difference between the complications of greatest 
concern between the physicians and people with diabetes 
is interesting. Physicians were predominantly interested 
in complications with the highest mortality, with cardio-
vascular disease being of greatest concern. In contrast, 
people with diabetes, were far more interested in com-
plications with an impact on the quality of life, notably 
retinopathy and nephropathy which is of major impor-
tance in clinical practice.
These microvascular complications, of greatest concern 
to our patients, have been demonstrated to be reduced 
by lifestyle changes including diet and exercise [15] and 
good metabolic control [16, 17]. If physicians focused on 
these quality of life-based discussions of complications 
rather than mortality-based discussions it addresses the 
greatest concern of patients, thereby improving engage-
ment. Further, emphasis on treatable complications may 
invoke better commitment to diet, exercise and pharma-
cological therapy regimens.
This commitment may reap rewards in other areas, 
notably the risk of ulcer, amputation and severe neu-
ropathy, in the diabetic foot. A recent multicentre study 
of 1455 people with diabetes in Brazil suggested a higher 
proportion of patients with neuropathic disease, predom-
inantly neuroischaemic in nature, and a smaller number 
of patients with isolated ischaemic disease [18], com-
pared to similar studies performed in the USA [19] and 
Western Europe [20].
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Likewise, the prevalence of erectile dysfunction is 
higher among Brazilians than Western Europeans, 
with up to 74.6% of men with T2DM being affected, 
as assessed by international index of erectile function 
(IIEF-5) score [21]. In our study, the potential impact 
of diabetes on sexual health and fertility was given sub-
stantially less time in Brazil, with only 49% of physicians 
including it in their overview of potential complications 
compared to 64.6% in the other countries surveyed. At 
best, this indicates that patients may not completely be 
aware of the risks and potential treatments, and at worst, 
this lack of understanding could be contributing to the 
high-risk prevalence in Brazilian men and reduced qual-
ity of life.
Study limitations
Although every effort was made to ensure the generalis-
ability of the populations sampled, by utilising an online 
survey with predefined quotas, we may have generated 
some selection bias towards participants who are more 
technologically aware, more so in the people with diabe-
tes than the physicians. However, we are more likely to 
have over-recruited the motivated and more educated, 
thus suggesting the true dissociation between physician 
and people with diabetes may be greater than repre-
sented here.
The use of the online questionnaire, however, is justi-
fied because it, for the first time, allowed survey of a large 
number of people with diabetes across six countries, 
specifically chosen to represent the different health care 
structures, from the entirely free at the point of delivery 
NHS service in the UK to the entirely private sector in 
the USA.
Conclusions
Clinical inertia represents a considerable barrier to opti-
mal diabetes treatment. A greater understanding of spe-
cific impediments to escalating care, particularly from 
the interactions between physicians and people with dia-
betes in Brazil, may help identify and therefore address 
the unmet needs of the population. Brazil offers more 
time than many other countries around the world to its 
newly diagnosed people with diabetes. However, we have 
highlighted that our principle concerns as health care 
providers, notably on preventing major cardiovascular 
events, are not the same as the priorities of our patients, 
who are more concerned about the microvascular com-
plications that will impact quality rather than quantity of 
life. Adapting our consultation strategies to incorporate 
these patient-focused topics may improve understanding 
of the condition and ultimately engagement in self-man-
agement of the disease.
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